Optimal Hydroxychloroquine Levels for Lupus Treatment
Publication Title: Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring
Summary
- Question
- This study investigated the optimal blood levels of hydroxychloroquine (HCQ) in patients with systemic lupus erythematosus (SLE), a chronic autoimmune disease that causes inflammation in various parts of the body. The researchers aimed to define a therapeutic range for HCQ blood levels to balance its efficacy in controlling disease activity while minimizing risks of toxicity, especially in patients with chronic kidney disease (CKD).
- Why it Matters
HCQ is a key treatment for SLE, helping reduce disease activity and prevent flares. However, prolonged use of HCQ carries risks, including eye and heart toxicity. Patients with CKD are at higher risk due to reduced ability to eliminate HCQ from the body. This study is important because it proposes a blood level range for HCQ that may improve treatment outcomes, reduce toxicity risks, and guide personalized dosing strategies for these patients.
- Methods
- The researchers analyzed data from 2,010 SLE patients across multiple international cohorts. Blood HCQ levels were measured, and patients were categorized based on HCQ levels and CKD stages. Logistic regression and statistical analyses were used to identify thresholds of HCQ levels associated with toxicity and saturation of therapeutic effects. The study also evaluated the relationship between kidney function and HCQ levels over time in patients with CKD.
- Key Findings
- The researchers identified a therapeutic range for HCQ blood levels between 750 and 1,150 ng/mL. Blood levels above 1,150 ng/mL were linked to higher toxicity risks without additional clinical benefits in reducing disease activity. Patients with CKD stage 3 or higher had a 2.3-fold increased likelihood of reaching these toxic levels, even with weight-based dosing. This highlights the need for dose adjustments or closer monitoring in patients with impaired kidney function.
- Implications
- These findings support the use of HCQ blood level monitoring to optimize dosing and minimize risks of toxicity in SLE patients. Monitoring could help identify patients at risk of HCQ-related complications, particularly those with CKD, and guide more personalized treatment approaches. Implementing HCQ level monitoring could improve adherence, reduce flares, and enhance patient outcomes while alleviating concerns about long-term toxicity.
- Next Steps
- The researchers recommend future longitudinal studies to validate HCQ blood level monitoring and its role in optimizing dosing for patients with CKD. They also suggest exploring dose adjustment strategies based on HCQ levels and kidney function, as well as testing the feasibility and cost-effectiveness of routine HCQ monitoring in clinical practice.
- Funding Information
This research was supported by the National Institutes of Health (grant 5K23-AR-084608-02). Additional funding was provided by the Lupus Foundation of America, Wisconsin Chapter, through a Research Award, and by the Rheumatology Research Foundation Innovation Research Award. Yale University also provided funding and support for this research.
Full Citation
Garg S, Blanchet B, Nguyen Y, Hollnagel F, Clarke A, Petri M, Urowitz M, Hanly J, Gordon C, Bae S, Romero‐Diaz J, Sanchez‐Guerrero J, Clarke A, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, Fortin P, Gladman D, Bruce I, Ginzler E, Dooley M, Ramsey‐Goldman R, Manzi S, Jönsen A, Alarcón G, Van Vollenhoven R, Aranow C, Le Guern V, Mackay M, Ruiz‐Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Buyon J, Chezel J, Puszkiel A, Costedoat‐Chalumeau N. Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring. Arthritis & Rheumatology 2026, 78: 1102-1113. PMID: 41367131, PMCID: PMC13129619, DOI: 10.1002/art.70010.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Shivani Garg, MD, PhD
First AuthorNathalie Costedoat‐Chalumeau
Last Author
Additional Yale School of Medicine Authors
Other Authors
Research Themes
Concepts
- Systemic Lupus International Collaborating Clinics;
- systemic lupus erythematosus;
- effective blood levels;
- higher risk of flares;
- reference ranges;
- high risk;
- risk of flare;
- levels of hydroxychloroquine;
- blood level measurements;
- blood level monitoring;
- logistic regression analysis;
- hydroxychloroquine dose;
- Collaborating Clinics;
- lupus erythematosus;
- drug monitoring;
- hydroxychloroquine;
- observational study;
- regression analysis;
- dose;
- routine monitoring;
- level monitoring;
- French study;
- erythematosus;
- cross-sectional data;
- lupus